MorphoSys gets FDA fast track status for lymphoma drug MOR208
DLBCL accounts for about 25% of all NHLs in the developed world and it occurs primarily in older individuals, while the disease can also occur in children and
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.
The pancreatic cancer treatment includes implanting living cells that have been encapsulated in pin-head sized, cellulose-based, protective cocoons through the use of the Cell-in-a-Box technology, followed by the
AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel Breath Powered delivery technology. The FDA has raised questions regarding the human
Results were presented in a poster presentation entitled "Novel synthetic RORgamma agonist compounds as a potential anti-tumor therapeutic approach" and will be highlighted in an oral presentation on
As part of this collaboration, Idera and PPMD intend to work together to conduct preclinical studies and develop a clinical development strategy for an investigational TLR antagonist candidate.
The trial showed that these patients with the most common type of EGFR mutation, (exon 19 deletion; del19), lived significantly longer after receiving first-line treatment with afatinib compared